
Contineum Therapeutics, Inc. (CTNM) Stock Ticker
CTNM right now
Market factors today
Unlock the full CTNM picture
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
CTNM stock facts
| Ticker symbol | CTNM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $472.5M |
| CEO | Carmine N. Stengone |
| Employees | 51 |
| Headquarters | San Diego, CA, US |
| IPO date | 2024-04-04 |
| Website | www.contineum-tx.com |
What you can see for CTNM on Tickr
Live CTNM price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CTNM report.
Rankings
FAQ
What is the ticker symbol for Contineum Therapeutics, Inc.?
The ticker symbol for Contineum Therapeutics, Inc. is CTNM, listed on the NASDAQ.
What is CTNM?
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary…